Delisted

Stopped trading. Last price we have: $90.00 on Dec 30, 2025. Fund positions aren't valued until we confirm what happened.

MRUS

MERUS N V

MRUS (MERUS N V) is held by 3 institutional investors as of Q4 2025. Top institutional shareholders: XTX Topco Ltd ($2.4M), Farther Finance Advisors, LLC ($90,900), Simplex Trading, LLC ($75,330).

No verdict yet — fewer than 2 funds hold MRUS.

Top Holders

Fund ownership
Fund holdings as of
Funds holding3
avg
Value of reported holdings$2.6M
Funds buying / selling
Not available
Checking access…
Action
Increased
26,768(+125.9%)$2.4M0.1%—
42
Increased
1,010(+92.4%)$90,9000.0%—
34
New
837$75,3300.0%—
33
Exited
0(-100.0%)$745,4260.0%—
0
Exited
0(-100.0%)$24M0.0%—
0
Exited
0(-100.0%)$275,2950.0%—
0
Exited
0(-100.0%)$268.3M0.0%—
0
Exited
0(-100.0%)$1.3M0.0%—
0
Exited
0(-100.0%)$207,2240.0%—
0
Exited
0(-100.0%)$19.8M0.0%—
0
Exited
0(-100.0%)$117.6M0.0%—
0
Exited
0(-100.0%)$98.4M0.0%—
0
Exited
0(-100.0%)$18.1M0.0%—
0
Exited
0(-100.0%)$11.5M0.0%—
0
Exited
0(-100.0%)$470,4680.0%—
0
Exited
0(-100.0%)$1.1M0.0%—
0
Exited
0(-100.0%)$1.5M0.0%—
0
Exited
0(-100.0%)$102.4M0.0%—
0
Exited
0(-100.0%)$8.4M0.0%—
0
Exited
0(-100.0%)$4.8M0.0%—
0

Showing 1-20 of 130

1 / 7
Latest insider trades
InsiderTradeTraded
GENMAB A/SBuy $102.1M
GENMAB A/SBuy $7359.1M
GENMAB A/SBuy $289K
GENMAB A/SBuy $13.8M
GENMAB A/SBuy $9.3M
GENMAB A/SBuy $54.4M
GENMAB A/SBuy $1.5M
GENMAB A/SBuy $6.4M
GENMAB A/SBuy $20.6M
GENMAB A/SBuy $14.6M
Loading Congress trades…
Latest activist filings
FilerStakeFiled
Paradigm BioCapital Advisors LP0.0%
Genmab A/S0.0%
RTW Investments, LP2.7%
Wellington Management Group LLP0.6%
FMR LLC3.7%
Commodore Capital LP4.7%
MRUSMRUSMERUS N V

Other Healthcare stocks held by institutions

Questions investors ask about MRUS

Who owns MRUS?

3 institutional investors held MRUS on December 31, 2025, led by XTX Topco Ltd ($2.4M), Farther Finance Advisors, LLC ($90,900) and Simplex Trading, LLC ($75,330).

How many hedge funds hold MRUS?

3 institutional investors reported MRUS in their 13F filings for the quarter ended December 31, 2025, $2.6M in all.

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Optional analytics helps us improve. How it’s used